Overview

AO-176 in Multiple Solid Tumor Malignancies

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

This is a first-in-human, Phase 1/2 multi-center, open-label, dose escalation and expansion study of AO-176 which will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and clinical effects of AO-176 in patients with advanced solid tumors.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Arch Oncology

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Paclitaxel
Pembrolizumab